Genentech, MedImmune end patent rift over Synagis

06/11/2008 | Bloomberg Businessweek · TheStreet.com

Genentech and MedImmune have reached an agreement to resolve a patent dispute over motavizumab and Synagis, a respiratory drug. The settlement allows MedImmune -- a unit of AstraZeneca PLC -- to receive licenses for selected pipeline products under a patent Genentech co-owns with City of Hope National Medical Center.

View Full Article in:

Bloomberg Businessweek · TheStreet.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Actuary
NTA Life
Addison, TX
Vice President - Government Products
Health Alliance Plan
Detroit, MI